{"entity":{"id":"genecraft","kind":"company","name":"GeneCraft","aka":["GeneCraft Inc."],"tldr":"GeneCraft is a Korean company testing a gene therapy, injected into the tumour, that restores a natural defence gene called RUNX3 to kill lung cancer cells driven by faulty KRAS.","summary":"GeneCraft Inc., headquartered at Chungbuk National University in Cheongju with an R&D centre in Seoul, develops gene therapies built on the tumour-suppressor research of its founder and co-CEO Suk-Chul Bae on RUNX3. Its lead programme RX001 (AAV-hRUNX3), made on its Ubi-AAV platform, is designed to selectively kill KRAS-mutated cancer cells; a phase 1 dose-escalation study gives a single intratumoral injection to patients with advanced KRAS-mutant non-small cell lung cancer (NCT06934590). Its first registered cancer trial, NCT06934590, was posted on ClinicalTrials.gov in April 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.genecraft.co.kr/"},{"label":"ClinicalTrials.gov: phase 1 trial of RX001 (NCT06934590)","url":"https://clinicaltrials.gov/study/NCT06934590"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":[],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website read on 29 October 2026; it still describes the company as pre-clinical. Founding year not stated. No financing amounts read. OnCo has no technology record for AAV gene therapy, so no technology is linked."],"hq":"Cheongju","country":"KR","companyType":"biotech","website":"https://www.genecraft.co.kr/","stage":"startup","investors":[],"funding":[]},"route":"/companies/genecraft/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}]}}